Spots Global Cancer Trial Database for bempegaldesleukin
Every month we try and update this database with for bempegaldesleukin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer | NCT03548467 | Locally Advance... | VB10.NEO Bempegaldesleuk... | 18 Years - | Nykode Therapeutics ASA | |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | NCT03138889 | Non-Small Cell ... | NKTR-214 Pembrolizumab NKTR-214 NKTR-214 Cisplatin Carboplatin Nab paclitaxel Paclitaxel Pemetrexed Atezolizumab | 18 Years - | Nektar Therapeutics | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | NCT04410445 | Melanoma Melanoma Stage ... Melanoma Stage ... Melanoma (Skin) | Bempegaldesleuk... Nivolumab | 12 Years - | Nektar Therapeutics | |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | NCT03729245 | Renal Cell Carc... Metastatic Rena... | bempegaldesleuk... sunitinib nivolumab cabozantinib | 18 Years - | Nektar Therapeutics | |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | NCT03138889 | Non-Small Cell ... | NKTR-214 Pembrolizumab NKTR-214 NKTR-214 Cisplatin Carboplatin Nab paclitaxel Paclitaxel Pemetrexed Atezolizumab | 18 Years - | Nektar Therapeutics | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | NCT03785925 | Urinary Bladder... Neoplasm Metast... | Bempegaldesleuk... Nivolumab | 18 Years - | Nektar Therapeutics | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer | NCT03548467 | Locally Advance... | VB10.NEO Bempegaldesleuk... | 18 Years - | Nykode Therapeutics ASA |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
